Please provide your email address to receive an email when new articles are posted on . Compared with married people, unmarried people were more likely to have a prolonged QT interval, according to ...

As more consumer-facing devices add features to measure the heart’s electrical activity, companies are looking for new ways to turn this data into valuable health information. AliveCor, a startup that ...

LQT-1213 is a first-in-class serum glucocorticoid regulated kinase 1 inhibitor. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LQT-1213, a first-in-class serum ...

Prolonged QT syndrome (a.k.a. Long QT Syndrome) consists of multiple different variations including long QT type 1-12, Romano-Ward syndrome and Jervell-Lange-Nielsen syndrome. A prolonged QT interval ...

February 19, 2009 (Portland, Oregon) — Both diabetes and QT-interval-prolonging medications were significant and independent risk factors for sudden cardiac death (SCD) among members of a ...

(HealthDay News) — Use of a computerized clinical decision support system (CDSS) may reduce the risk of prolonged QT c interval in hospitalized patients at risk for torsades de pointes, according to ...

SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., July 7, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today ...

ROTTERDAM, the NETHERLANDS — A new analysis of participants in a population-based cohort study suggests at least two ECGs might be useful to stratify individuals at risk for sudden cardiac death (SCD) ...

Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: ...

The diagnostics advisory committee considered evidence on KardiaMobile 6L for measuring QT interval from several sources, including an early value assessment report, cost and resource use report and ...

Results to be Included in BYDUREON TM New Drug Application Resubmission in the Third Quarter of 2011 SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.--(BUSINESS WIRE)--Amylin Pharmaceuticals, Inc. (Nasdaq: ...